Amgen Report Results for ABP 959 in Clinical Trial for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Shots:
- The company presented the results from the parallel & crossover comparisons along with the PK analysis of ABP 959 vs Soliris in patients with PNH. The results were presented by the company at the ASH 2023
- The results from both the parallel & crossover comparisons depicted similar efficacy data as determined by hemolysis in patients along with a similar PK between the 2 treatments seen through the analyses of serum total & unbound PK concentrations
- ABP 959 has already been approved in the EU with brand name Bekemv whereas its originator Soliris is approved in many indications incl. PNH, aHUS, gMG & NSOD. Post settlement with Alexion biosimilar can’t be launched in US till Mar 1, 2025
Ref: Amgen | Image: Amgen
Related News:- Q32 Bio Signs an Agreement with Amgen to Retrieve the Rights to Bempikibart (ADX-914) for Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
